Mesenchymal stem cells fight the new coronavirus epidemic! Beike Biotechnology and several medical institutions in Yunnan published the latest paper

Posted on 2020-04-30
12:00 am

According to the COVID-19 epidemic statistics from Johns Hopkins University in the United States, as of 10 a.m. on April 30, the number of confirmed cases of COVID-19 worldwide reached 3.1 million. Although the domestic epidemic is gradually under control, the situation abroad remains severe. In the absence of specific drugs and vaccines, how to effectively treat severely ill patients and reduce mortality is the focus of everyone’s attention.

During the epidemic, Beike Biotechnology is also actively involved in technological research. The clinical research on mesenchymal stem cells to treat critically ill patients with new coronary pneumonia jointly carried out with many medical institutions in Yunnan has also achieved phased results and published “Treatment of novel coronavirus pneumonia using human umbilical cord mesenchymal stem cells combined with antiviral and other methods” article.

Beike Biotech published the latest paper in cooperation with many medical institutions in Yunnan

The study was sponsored by Shenzhen Beike Biotechnology Co., Ltd. provides clinical-grade hUC-MSC for free (China Institute for Food and Drug Control verification report number: SH201401060). On the basis of conventional treatment, a 70-year-old female patient with severe COVID-19 was treated. baseline;”>Three intravenous infusions of human umbilical cord mesenchymal stem cells revealed thatStem cell treatment reduced the levels of major inflammatory factors such as IL-6 and C-reactive protein (CRP). During the infusion period, the ratio of neutrophils to lymphocytes continued to decline, and the absolute values of T cells, NK cells and B cells continued to rise. CT imaging results showed that the inflammatory response in the lungs gradually subsided; no adverse reactions were seen.

Article speculationHuman umbilical cord mesenchymal stem cells may benefit COVID-19 patients mainly through the following aspects:

(1) font-stretch: inherit; font-size: inherit; line-height: inherit; font-family: inherit; vertical-align: baseline;”>Homing and repair of damaged tissue may be mainly achieved through the secretion of factors that promote tissue regeneration;

（2） Inhibit inflammatory response, which may be mainly through the secretion of factors that inhibit inflammation and the neutralization of expression of IL-6, G-CSF and other inflammatory factor receptors to reduce inflammation;

(3) The above functionsProvides a good environment for the decline of neutrophils and the proliferation of lymphocytes.

Combined with the previous research results of the author and other research groups, the author of the article believes thatUmbilical cord mesenchymal stem cells have important application prospects in the treatment of severe and critically ill patients with COVID-19.

Research status of mesenchymal stem cells in combating COVID-19

In the treatment of severe COVID-19 patients, mesenchymal stem cells (Mesenchymal stem cells) cells (MSCs) have played an important role in their powerful immune regulation and improvement of the body’s microenvironment, and have become a current research hotspot in the biomedical field. Many authoritative news media have reported their clinical research progress in patients with severe COVID-19 pneumonia (Click to view details).

In addition, in March 2020, Beike Biotechnology and Shenzhen Third People’s Hospital (the only designated hospital in Shenzhen to treat patients with new coronavirus pneumonia) declared “Clinical Research on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe Pneumonia Caused by Coronavirus” project, won the Guangdong Provincial Department of Science and Technology’s 2020 Guangdong Provincial Emergency Response Project for the Prevention and Control of New Coronavirus Science and Technology (Click to view details); A number of clinical trials of mesenchymal stem cells in the treatment of COVID-19 have also been carried out at home and abroad (Click to view details).

With the deepening of research, mesenchymal stem cells have been applied in the treatment of a variety of refractory diseases. Nowadays, in the face of the raging new coronavirus, mesenchymal stem cells have excellent performance in the treatment of critically ill patients with new coronavirus pneumonia and play an important role in this anti-viral battle. We have reason to believe that mesenchymal stem cells can also contribute in more fields in the future.